NeuroSense Therapeutics (NRSN) FDA Approvals $1.56 -0.13 (-7.40%) Closing price 04:00 PM EasternExtended Trading$1.56 -0.01 (-0.58%) As of 04:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings NeuroSense Therapeutics' Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by NeuroSense Therapeutics (NRSN). Over the past two years, NeuroSense Therapeutics has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as PrimeC. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. PrimeC FDA Regulatory Timeline and Events PrimeC is a drug developed by NeuroSense Therapeutics for the following indication: Amyotrophic lateral sclerosis. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. primary efficacy endpoint - June 29,2026Primary Efficacy Endpoint Phase 2bDrug: PrimeCAnnounced Date: June 29, 2026Indication: Amyotrophic lateral sclerosisAnnouncementNeuroSense Therapeutics announced that its Phase 2b PARADIGM study of PrimeC in amyotrophic lateral sclerosis (ALS) has successfully met its primary efficacy endpoint, demonstrating a statistically significant reduction in TDP-43 levels compared to placebo.AI SummaryNeuroSense Therapeutics said its Phase 2b PARADIGM study of PrimeC in amyotrophic lateral sclerosis (ALS) met its main goal. The treatment showed a statistically significant drop in TDP-43 levels compared with placebo. TDP-43 is a key protein linked to ALS and is found in more than 97% of cases, so lowering it suggests PrimeC may affect a major cause of the disease. The company said this result adds biological support to earlier study findings and suggests TDP-43 could be useful as a biomarker for tracking treatment response. NeuroSense is now preparing its global Phase 3 PARAGON trial and continuing regulatory work in several regions. ALS is a serious, fatal nerve disease with no cure, making new treatment options urgently needed.Read AnnouncementSurvival data - March 9,2026Survival Data Phase 2bDrug: PrimeCAnnounced Date: March 9, 2026Indication: Amyotrophic lateral sclerosisAnnouncementNeuroSense Therapeutics announced that the recently reported long-term survival data from its Phase 2b PARADIGM trial of PrimeC in amyotrophic lateral sclerosis (ALS) will be presented at a leading scientific conference on March 9, 2026.AI SummaryNeuroSense Therapeutics announced that long-term survival results from its Phase 2b PARADIGM trial of PrimeC in amyotrophic lateral sclerosis (ALS) will be presented at The Muscular Dystrophy Association (MDA) Clinical & Scientific Conference on March 9, 2026. A Cox proportional hazards analysis showed a statistically significant 65% reduction in risk of death for PrimeC (hazard ratio 0.35, p=0.0037). Kaplan–Meier estimates indicated a greater than 14‑month median survival benefit from randomization (36.3 months versus 21.4 months; log‑rank p=0.0218). The data will be presented during the “Advancing ALS Therapeutics: Targets, Tools, and Trial Readiness” session by Dr. Jinsy Andrews, a leader in ALS clinical research and member of NeuroSense’s scientific advisory board. NeuroSense said the newly analyzed survival findings strengthen the clinical dataset supporting PrimeC and inform planning for the next-stage, Phase 3 study. Read AnnouncementSurvival data - February 18,2026Survival Data Drug: PrimeCAnnounced Date: February 18, 2026Indication: Amyotrophic lateral sclerosisAnnouncementNeuroSense Therapeutics Ltd announced the availability of additional long-term survival data from its previously completed PARADIGM Phase 2b clinical trial evaluating PrimeC in patients with amyotrophic lateral sclerosis (ALS).AI SummaryNeuroSense Therapeutics announced additional long-term survival data from its completed PARADIGM Phase 2b trial of PrimeC in ALS patients. An extended follow-up showed a clinically meaningful and statistically significant improvement in overall survival for those treated with PrimeC compared with patients originally assigned to placebo. Kaplan–Meier estimates showed median survival of 36.3 months for patients who received PrimeC continuously versus 21.4 months for those who started on placebo and later crossed over — a more than 14‑month gain, roughly a 70% increase. The survival curves remained separated over time (log‑rank p = 0.0218). A Cox model, adjusted for baseline risk, found PrimeC reduced the risk of death by 65% (hazard ratio 0.35; 95% CI 0.17–0.71; p = 0.0037). NeuroSense said the results support PrimeC’s durable, disease‑modifying potential and strengthen the case for advancing into late‑stage development while engaging with regulatory authorities.Read AnnouncementAnalysis - December 22,2025Analysis Phase 2Drug: PrimeCAnnounced Date: December 22, 2025Indication: Amyotrophic lateral sclerosisAnnouncementNeuroSense Therapeutics today reported completion of the safety analysis from its proof-of-concept Phase 2, randomized, double-blind, placebo-controlled NST-AD-001 study of PrimeC combination in Alzheimer's disease.AI SummaryNeuroSense Therapeutics announced completion of the safety analysis from its proof-of-concept Phase 2, randomized, double-blind, placebo-controlled NST-AD-001 study of PrimeC in Alzheimer’s disease. The analysis showed a favorable tolerability profile: no serious adverse events were reported and no new or unexpected safety signals were identified. As an exploratory study, clinical outcome measures are descriptive. NeuroSense will analyze clinical observations together with biomarker data to provide a more complete interpretation of the results. The company expects to report those clinical and biomarker findings in the first quarter of 2026. PrimeC is an oral extended-release fixed-dose combination of ciprofloxacin and celecoxib, designed to target multiple disease mechanisms tied to neuron degeneration, inflammation, iron accumulation and RNA dysregulation. The study is intended to assess whether this multi-target approach can improve treatment options for people with Alzheimer’s disease.Read Announcementreview - November 24,2025Review INDDrug: PrimeCAnnounced Date: November 24, 2025Indication: Amyotrophic lateral sclerosisAnnouncementNeuroSense Therapeutics announced that the U.S. Food and Drug Administration (FDA) has completed the review of the Investigational New Drug (IND) amendment application and authorized the Company to initiate the pivotal Phase 3 clinical trial for the evaluation of its lead drug candidate, PrimeC, for the treatment of amyotrophic lateral sclerosis (ALS).AI SummaryNeuroSense said the U.S. Food and Drug Administration completed its review of the company’s IND amendment and authorized initiation of a pivotal Phase 3 trial of PrimeC for amyotrophic lateral sclerosis (ALS). With FDA clearance, NeuroSense is preparing to start the trial and aims to enroll the first patient in the coming months once it secures the necessary resources. The global Phase 3 trial, PARAGON, is powered at over 95% for its primary endpoint and will build on NeuroSense’s Phase 2b PARADIGM findings. The study plans to enroll 300 people with ALS randomized 2:1 to PrimeC or placebo in a 12‑month, double‑blind, placebo‑controlled design with an open‑label extension. The adaptive design allows interim analyses to adjust sample size and assess early efficacy or futility. PrimeC is an oral extended‑release fixed‑dose combination of ciprofloxacin and celecoxib designed to target multiple disease mechanisms. FDA authorization to begin PARAGON is a key step toward testing whether PrimeC can slow ALS progression.Read AnnouncementFindings Update - October 6,2025Findings Update Drug: PrimeCAnnounced Date: October 6, 2025Indication: Amyotrophic lateral sclerosisAnnouncementNeuroSense Therapeutics Ltd. announced new positive findings based on plasma samples from its Phase-2b PARADIGM study.AI SummaryNeuroSense Therapeutics Ltd. announced new positive findings from plasma samples in its Phase-2b PARADIGM study of PrimeC, a novel extended-release oral therapy. Results showed that PrimeC treatment led to statistically significant reductions in Alzheimer’s disease–associated microRNAs: miR-146a-5p (p=0.007), miR-21-5p (p=0.003), miR-let-7a-5p (p=0.028) and miR-let-7e-5p (p=0.006). The placebo group showed no meaningful changes. These microRNAs regulate genes involved in brain inflammation, amyloid and tau buildup, and nerve cell damage. Lowering them suggests PrimeC can directly target key pathways in Alzheimer’s and may act as a disease-modifying therapy. “These biomarker data provide a clearer view of how our novel combination modulates Alzheimer’s disease pathways,” said Alon Ben-Noon, CEO of NeuroSense. “The magnitude and consistency of the observed miRNA changes are highly encouraging and will inform the design of our follow-on Alzheimer’s study.”Read Announcementnew analyses - September 2,2025New Analyses Phase 2bDrug: PrimeCAnnounced Date: September 2, 2025Indication: Amyotrophic lateral sclerosisAnnouncementNeuroSense Therapeutics Ltd announced a new analysis of 18-month data from its Phase 2b PARADIGM study of PrimeC in ALS.AI SummaryCould you please provide the FDA-related news article text you’d like summarized?Read AnnouncementProvided Update - May 7,2025Provided Update Drug: PrimeCAnnounced Date: May 7, 2025Indication: Amyotrophic lateral sclerosisAnnouncementNeuroSense Therapeutics Ltd. announced that it has successfully scaled-up its production of PrimeC to commercial scale, marking a significant step toward bringing this potential disease-modifying ALS therapy to patients, following the promising efficacy data demonstrated in the Phase 2b PARADIGM study.AI Summary NeuroSense Therapeutics Ltd. has reached a major milestone by successfully scaling up its production of PrimeC to a commercial level. This scale-up comes on the heels of promising results from the Phase 2b PARADIGM study, highlighting PrimeC’s potential as a disease-modifying therapy for ALS patients. The achievement builds on robust improvements in their manufacturing process, ensuring that all analytical methods for product release and stability have been fully validated. By partnering with a global Contract Development and Manufacturing Organization (CDMO), NeuroSense secured a dependable supply chain for future production needs. The validated manufacturing process also supports a shelf life of at least 36 months at room temperature. This progress marks a significant step toward bringing PrimeC to market, aiming to address a critical unmet need for new therapeutic options for those suffering from ALS. Read AnnouncementProvided Update - April 24,2025Provided Update Drug: PrimeCAnnounced Date: April 24, 2025Indication: Amyotrophic lateral sclerosisAnnouncementNeuroSense Therapeutics issued a shareholder letter from Chief Executive Officer Alon Ben-Noon.AI SummaryNeuroSense Therapeutics’ CEO, Alon Ben-Noon, issued a shareholder letter outlining key developments for the company. In his message, he highlighted the upcoming launch of the global Phase 3 clinical trial for PrimeC in ALS, planned for the second half of 2025. Ben-Noon emphasized that advancing this pivotal study is a major step forward in providing robust clinical data for the therapy and its potential impact on patients. The letter also provided an update on progress with the Canadian regulatory pathway, where discussions with Health Canada are exploring accelerated access through a Notice of Compliance with Conditions (NOC/c). Additionally, Ben-Noon expressed optimism about ongoing strategic partnership discussions with a global pharmaceutical company, noting that although finalizing this multi-regional deal has taken more time than expected, it could transform the company operationally and financially. He thanked shareholders for their continued support as NeuroSense moves forward in its mission.Read AnnouncementFindings Update - April 9,2025Findings Update Phase 2bDrug: PrimeCAnnounced Date: April 9, 2025Indication: Amyotrophic lateral sclerosisAnnouncementNeuroSense Therapeutics, Ltd. announced promising new findings from its Phase 2b PARADIGM clinical trial.AI SummaryNeuroSense Therapeutics, Ltd. announced promising findings from its Phase 2b PARADIGM clinical trial for its ALS treatment, PrimeC. The study showed that PrimeC consistently downregulated 161 mature microRNAs (miRNAs) in treated patients, including key miRNAs like miR-199 and miR-181 that are linked to disease progression and neuroinflammation in ALS. These results suggest that PrimeC could help slow the progression of ALS by targeting molecular pathways that drive inflammation and motor neuron degeneration. The modulation of these miRNAs reinforces the potential of PrimeC as a transformative, multi-targeted therapy for ALS. The data builds on earlier clinical observations, supporting PrimeC’s ability to improve survival rates and reduce disease progression, and provides a strong foundation for further studies to explore its impact on miRNA maturation and additional neurodegenerative diseases.Read AnnouncementProvided Update - April 7,2025Provided Update Drug: PrimeCAnnounced Date: April 7, 2025Indication: Amyotrophic lateral sclerosisAnnouncementNeuroSense Therapeutics Ltd. provides a business update.AI SummaryNeuroSense Therapeutics Ltd. provided a business update highlighting major progress with its lead candidate, PrimeC, for treating amyotrophic lateral sclerosis (ALS). The company announced that its Phase 2b study met both primary and secondary endpoints, showing a 33% slower disease progression over 18 months and a 58% improvement in survival rates, while also preserving key functions like speaking and swallowing. PrimeC demonstrated a favorable safety and tolerability profile, which supports its potential to modify the course of ALS. Following a Type C meeting with the FDA, NeuroSense received positive feedback on the Phase 3 study design, now slated to begin in 2025. The company is in ongoing partnership discussions to advance PrimeC towards regulatory approval and eventual commercialization, including plans to file for early commercialization in Canada.Read AnnouncementData Presentation - April 4,2025Data Presentation Phase 2bDrug: PrimeCAnnounced Date: April 4, 2025Indication: Amyotrophic lateral sclerosisAnnouncementNeuroSense Therapeutics, Ltd. announced that two members of its Scientific Advisory Board will present new data from the Company's Phase 2b trial during the General Neurology and Late Breaker sessions at the 77th Annual American Academy of Neurology (AAN) Meeting.AI SummaryNeuroSense Therapeutics, Ltd. announced that two members of its Scientific Advisory Board will present new data from the company’s Phase 2b trial at the 77th Annual American Academy of Neurology (AAN) Meeting. The presentations will take place during the General Neurology and Late Breaker sessions in San Diego, CA, on April 8, 2025. Dr. Jeremy Shefner will share clinical data demonstrating PrimeC’s safety, tolerability, and efficacy as an oral candidate for ALS, highlighting its potential to reduce ALS progression while engaging multiple biomarker endpoints. Meanwhile, Dr. Jeffrey Rosenfeld will present insights on microRNA modulation and iron-related markers in ALS treatment, shedding light on the mechanism behind PrimeC’s effects. These presentations underscore the company’s focus on advancing a disease-modifying therapy for ALS.Read AnnouncementProvided Update - March 20,2025Provided Update Drug: PrimeCAnnounced Date: March 20, 2025Indication: Amyotrophic lateral sclerosisAnnouncementNeuroSense Therapeutics Ltd. announced significant progress toward the early commercialization of PrimeC in Canada.AI SummaryNeuroSense Therapeutics Ltd. announced significant progress toward the early commercialization of its lead ALS therapy, PrimeC, in Canada. Health Canada has invited the company to a pre-New Drug Submission meeting to discuss a potential regulatory pathway for PrimeC. The company is targeting approval by the first half of 2026, which could pave the way for earlier market entry. PrimeC is an innovative, extended-release oral formulation that combines ciprofloxacin and celecoxib. It has shown strong clinical efficacy in trials, including reductions in disease progression and improvements in survival rates. NeuroSense estimates that PrimeC could generate peak annual revenues of $100 to $150 million in the Canadian market alone. This Canadian regulatory development is a critical step in the company’s overall strategy to bring a breakthrough treatment for Amyotrophic Lateral Sclerosis to patients in need.Read AnnouncementPositive Results - December 4,2024Positive Results Drug: PrimeCAnnounced Date: December 4, 2024Indication: Amyotrophic lateral sclerosisAnnouncementNeuroSense Therapeutics announce today statistically significant positive results from the 18-month data analysis of the PARADIGM study, evaluating the efficacy of PrimeC in the treatment of Amyotrophic Lateral Sclerosis (ALS).AI Summary NeuroSense Therapeutics announced statistically significant positive results from the 18‐month analysis of its PARADIGM study evaluating PrimeC in ALS treatment. Patients who received PrimeC from the beginning experienced a 33% slower progression of the disease, as shown by nearly an 8-point improvement on the ALS Functional Rating Scale-Revised compared to those who started on placebo before switching to PrimeC. Additionally, continuous treatment with PrimeC led to a striking 58% improvement in survival rates. These results, with a p-value of 0.007, underscore the potential of PrimeC to redefine the standard of care for ALS by offering a more effective approach to slowing disease progression and extending patient survival. Read Announcement NeuroSense Therapeutics FDA Events - Frequently Asked Questions Has NeuroSense Therapeutics received FDA approval? As of now, NeuroSense Therapeutics (NRSN) has not received any FDA approvals for its therapy in the last two years. What drugs has NeuroSense Therapeutics submitted to the FDA? In the past two years, NeuroSense Therapeutics (NRSN) has reported FDA regulatory activity for PrimeC. What is the most recent FDA event for NeuroSense Therapeutics? The most recent FDA-related event for NeuroSense Therapeutics occurred on June 29, 2026, involving PrimeC. The update was categorized as "primary efficacy endpoint," with the company reporting: "NeuroSense Therapeutics announced that its Phase 2b PARADIGM study of PrimeC in amyotrophic lateral sclerosis (ALS) has successfully met its primary efficacy endpoint, demonstrating a statistically significant reduction in TDP-43 levels compared to placebo." What conditions do NeuroSense Therapeutics' current drugs treat? Currently, NeuroSense Therapeutics has one therapy (PrimeC) targeting the following condition: Amyotrophic lateral sclerosis. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events Aclaris Therapeutics FDA EventsBioVie FDA EventsBioLineRx FDA EventsCorbus Pharmaceuticals FDA EventsCardiff Oncology FDA EventsCytokinetics FDA EventsEstrella Immunopharma FDA EventsCybin FDA EventsIN8bio FDA EventsLantheus FDA EventsMediWound FDA EventsMetaVia FDA EventsRadiopharm Theranostics FDA EventsRein Therapeutics FDA EventsNuvation Bio FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies TScan Therapeutics FDA Events Passage Bio FDA Events BioVie FDA Events Vyome FDA Events Chemomab Therapeutics FDA Events Phio Pharmaceuticals FDA Events IN8bio FDA Events VistaGen Therapeutics FDA Events GT Biopharma FDA Events MetaVia FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare Stocks FDA progress for NASDAQ:NRSN last updated on 6/29/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersMy $247 scanner for $7Bill Poulos is cutting the price of his $247 Instant Scanner to $7 for Black Friday. It's a one-time payment t...Profits Run | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredThe $40 trillion number nobody won on Tuesday will touchDemocrats took the House and Senate on election night, but the $40 trillion national debt and the $1 trillion ...Vault Metal | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredMicroscopic footage reveals immune cells destroying cancer cellsTime-lapse footage from a recent clinical study shows Natural Killer cells attacking and eliminating cancer ce...Market Tactic | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroSense Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeuroSense Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
primary efficacy endpoint - June 29,2026Primary Efficacy Endpoint Phase 2bDrug: PrimeCAnnounced Date: June 29, 2026Indication: Amyotrophic lateral sclerosisAnnouncementNeuroSense Therapeutics announced that its Phase 2b PARADIGM study of PrimeC in amyotrophic lateral sclerosis (ALS) has successfully met its primary efficacy endpoint, demonstrating a statistically significant reduction in TDP-43 levels compared to placebo.AI SummaryNeuroSense Therapeutics said its Phase 2b PARADIGM study of PrimeC in amyotrophic lateral sclerosis (ALS) met its main goal. The treatment showed a statistically significant drop in TDP-43 levels compared with placebo. TDP-43 is a key protein linked to ALS and is found in more than 97% of cases, so lowering it suggests PrimeC may affect a major cause of the disease. The company said this result adds biological support to earlier study findings and suggests TDP-43 could be useful as a biomarker for tracking treatment response. NeuroSense is now preparing its global Phase 3 PARAGON trial and continuing regulatory work in several regions. ALS is a serious, fatal nerve disease with no cure, making new treatment options urgently needed.Read Announcement
Survival data - March 9,2026Survival Data Phase 2bDrug: PrimeCAnnounced Date: March 9, 2026Indication: Amyotrophic lateral sclerosisAnnouncementNeuroSense Therapeutics announced that the recently reported long-term survival data from its Phase 2b PARADIGM trial of PrimeC in amyotrophic lateral sclerosis (ALS) will be presented at a leading scientific conference on March 9, 2026.AI SummaryNeuroSense Therapeutics announced that long-term survival results from its Phase 2b PARADIGM trial of PrimeC in amyotrophic lateral sclerosis (ALS) will be presented at The Muscular Dystrophy Association (MDA) Clinical & Scientific Conference on March 9, 2026. A Cox proportional hazards analysis showed a statistically significant 65% reduction in risk of death for PrimeC (hazard ratio 0.35, p=0.0037). Kaplan–Meier estimates indicated a greater than 14‑month median survival benefit from randomization (36.3 months versus 21.4 months; log‑rank p=0.0218). The data will be presented during the “Advancing ALS Therapeutics: Targets, Tools, and Trial Readiness” session by Dr. Jinsy Andrews, a leader in ALS clinical research and member of NeuroSense’s scientific advisory board. NeuroSense said the newly analyzed survival findings strengthen the clinical dataset supporting PrimeC and inform planning for the next-stage, Phase 3 study. Read Announcement
Survival data - February 18,2026Survival Data Drug: PrimeCAnnounced Date: February 18, 2026Indication: Amyotrophic lateral sclerosisAnnouncementNeuroSense Therapeutics Ltd announced the availability of additional long-term survival data from its previously completed PARADIGM Phase 2b clinical trial evaluating PrimeC in patients with amyotrophic lateral sclerosis (ALS).AI SummaryNeuroSense Therapeutics announced additional long-term survival data from its completed PARADIGM Phase 2b trial of PrimeC in ALS patients. An extended follow-up showed a clinically meaningful and statistically significant improvement in overall survival for those treated with PrimeC compared with patients originally assigned to placebo. Kaplan–Meier estimates showed median survival of 36.3 months for patients who received PrimeC continuously versus 21.4 months for those who started on placebo and later crossed over — a more than 14‑month gain, roughly a 70% increase. The survival curves remained separated over time (log‑rank p = 0.0218). A Cox model, adjusted for baseline risk, found PrimeC reduced the risk of death by 65% (hazard ratio 0.35; 95% CI 0.17–0.71; p = 0.0037). NeuroSense said the results support PrimeC’s durable, disease‑modifying potential and strengthen the case for advancing into late‑stage development while engaging with regulatory authorities.Read Announcement
Analysis - December 22,2025Analysis Phase 2Drug: PrimeCAnnounced Date: December 22, 2025Indication: Amyotrophic lateral sclerosisAnnouncementNeuroSense Therapeutics today reported completion of the safety analysis from its proof-of-concept Phase 2, randomized, double-blind, placebo-controlled NST-AD-001 study of PrimeC combination in Alzheimer's disease.AI SummaryNeuroSense Therapeutics announced completion of the safety analysis from its proof-of-concept Phase 2, randomized, double-blind, placebo-controlled NST-AD-001 study of PrimeC in Alzheimer’s disease. The analysis showed a favorable tolerability profile: no serious adverse events were reported and no new or unexpected safety signals were identified. As an exploratory study, clinical outcome measures are descriptive. NeuroSense will analyze clinical observations together with biomarker data to provide a more complete interpretation of the results. The company expects to report those clinical and biomarker findings in the first quarter of 2026. PrimeC is an oral extended-release fixed-dose combination of ciprofloxacin and celecoxib, designed to target multiple disease mechanisms tied to neuron degeneration, inflammation, iron accumulation and RNA dysregulation. The study is intended to assess whether this multi-target approach can improve treatment options for people with Alzheimer’s disease.Read Announcement
review - November 24,2025Review INDDrug: PrimeCAnnounced Date: November 24, 2025Indication: Amyotrophic lateral sclerosisAnnouncementNeuroSense Therapeutics announced that the U.S. Food and Drug Administration (FDA) has completed the review of the Investigational New Drug (IND) amendment application and authorized the Company to initiate the pivotal Phase 3 clinical trial for the evaluation of its lead drug candidate, PrimeC, for the treatment of amyotrophic lateral sclerosis (ALS).AI SummaryNeuroSense said the U.S. Food and Drug Administration completed its review of the company’s IND amendment and authorized initiation of a pivotal Phase 3 trial of PrimeC for amyotrophic lateral sclerosis (ALS). With FDA clearance, NeuroSense is preparing to start the trial and aims to enroll the first patient in the coming months once it secures the necessary resources. The global Phase 3 trial, PARAGON, is powered at over 95% for its primary endpoint and will build on NeuroSense’s Phase 2b PARADIGM findings. The study plans to enroll 300 people with ALS randomized 2:1 to PrimeC or placebo in a 12‑month, double‑blind, placebo‑controlled design with an open‑label extension. The adaptive design allows interim analyses to adjust sample size and assess early efficacy or futility. PrimeC is an oral extended‑release fixed‑dose combination of ciprofloxacin and celecoxib designed to target multiple disease mechanisms. FDA authorization to begin PARAGON is a key step toward testing whether PrimeC can slow ALS progression.Read Announcement
Findings Update - October 6,2025Findings Update Drug: PrimeCAnnounced Date: October 6, 2025Indication: Amyotrophic lateral sclerosisAnnouncementNeuroSense Therapeutics Ltd. announced new positive findings based on plasma samples from its Phase-2b PARADIGM study.AI SummaryNeuroSense Therapeutics Ltd. announced new positive findings from plasma samples in its Phase-2b PARADIGM study of PrimeC, a novel extended-release oral therapy. Results showed that PrimeC treatment led to statistically significant reductions in Alzheimer’s disease–associated microRNAs: miR-146a-5p (p=0.007), miR-21-5p (p=0.003), miR-let-7a-5p (p=0.028) and miR-let-7e-5p (p=0.006). The placebo group showed no meaningful changes. These microRNAs regulate genes involved in brain inflammation, amyloid and tau buildup, and nerve cell damage. Lowering them suggests PrimeC can directly target key pathways in Alzheimer’s and may act as a disease-modifying therapy. “These biomarker data provide a clearer view of how our novel combination modulates Alzheimer’s disease pathways,” said Alon Ben-Noon, CEO of NeuroSense. “The magnitude and consistency of the observed miRNA changes are highly encouraging and will inform the design of our follow-on Alzheimer’s study.”Read Announcement
new analyses - September 2,2025New Analyses Phase 2bDrug: PrimeCAnnounced Date: September 2, 2025Indication: Amyotrophic lateral sclerosisAnnouncementNeuroSense Therapeutics Ltd announced a new analysis of 18-month data from its Phase 2b PARADIGM study of PrimeC in ALS.AI SummaryCould you please provide the FDA-related news article text you’d like summarized?Read Announcement
Provided Update - May 7,2025Provided Update Drug: PrimeCAnnounced Date: May 7, 2025Indication: Amyotrophic lateral sclerosisAnnouncementNeuroSense Therapeutics Ltd. announced that it has successfully scaled-up its production of PrimeC to commercial scale, marking a significant step toward bringing this potential disease-modifying ALS therapy to patients, following the promising efficacy data demonstrated in the Phase 2b PARADIGM study.AI Summary NeuroSense Therapeutics Ltd. has reached a major milestone by successfully scaling up its production of PrimeC to a commercial level. This scale-up comes on the heels of promising results from the Phase 2b PARADIGM study, highlighting PrimeC’s potential as a disease-modifying therapy for ALS patients. The achievement builds on robust improvements in their manufacturing process, ensuring that all analytical methods for product release and stability have been fully validated. By partnering with a global Contract Development and Manufacturing Organization (CDMO), NeuroSense secured a dependable supply chain for future production needs. The validated manufacturing process also supports a shelf life of at least 36 months at room temperature. This progress marks a significant step toward bringing PrimeC to market, aiming to address a critical unmet need for new therapeutic options for those suffering from ALS. Read Announcement
Provided Update - April 24,2025Provided Update Drug: PrimeCAnnounced Date: April 24, 2025Indication: Amyotrophic lateral sclerosisAnnouncementNeuroSense Therapeutics issued a shareholder letter from Chief Executive Officer Alon Ben-Noon.AI SummaryNeuroSense Therapeutics’ CEO, Alon Ben-Noon, issued a shareholder letter outlining key developments for the company. In his message, he highlighted the upcoming launch of the global Phase 3 clinical trial for PrimeC in ALS, planned for the second half of 2025. Ben-Noon emphasized that advancing this pivotal study is a major step forward in providing robust clinical data for the therapy and its potential impact on patients. The letter also provided an update on progress with the Canadian regulatory pathway, where discussions with Health Canada are exploring accelerated access through a Notice of Compliance with Conditions (NOC/c). Additionally, Ben-Noon expressed optimism about ongoing strategic partnership discussions with a global pharmaceutical company, noting that although finalizing this multi-regional deal has taken more time than expected, it could transform the company operationally and financially. He thanked shareholders for their continued support as NeuroSense moves forward in its mission.Read Announcement
Findings Update - April 9,2025Findings Update Phase 2bDrug: PrimeCAnnounced Date: April 9, 2025Indication: Amyotrophic lateral sclerosisAnnouncementNeuroSense Therapeutics, Ltd. announced promising new findings from its Phase 2b PARADIGM clinical trial.AI SummaryNeuroSense Therapeutics, Ltd. announced promising findings from its Phase 2b PARADIGM clinical trial for its ALS treatment, PrimeC. The study showed that PrimeC consistently downregulated 161 mature microRNAs (miRNAs) in treated patients, including key miRNAs like miR-199 and miR-181 that are linked to disease progression and neuroinflammation in ALS. These results suggest that PrimeC could help slow the progression of ALS by targeting molecular pathways that drive inflammation and motor neuron degeneration. The modulation of these miRNAs reinforces the potential of PrimeC as a transformative, multi-targeted therapy for ALS. The data builds on earlier clinical observations, supporting PrimeC’s ability to improve survival rates and reduce disease progression, and provides a strong foundation for further studies to explore its impact on miRNA maturation and additional neurodegenerative diseases.Read Announcement
Provided Update - April 7,2025Provided Update Drug: PrimeCAnnounced Date: April 7, 2025Indication: Amyotrophic lateral sclerosisAnnouncementNeuroSense Therapeutics Ltd. provides a business update.AI SummaryNeuroSense Therapeutics Ltd. provided a business update highlighting major progress with its lead candidate, PrimeC, for treating amyotrophic lateral sclerosis (ALS). The company announced that its Phase 2b study met both primary and secondary endpoints, showing a 33% slower disease progression over 18 months and a 58% improvement in survival rates, while also preserving key functions like speaking and swallowing. PrimeC demonstrated a favorable safety and tolerability profile, which supports its potential to modify the course of ALS. Following a Type C meeting with the FDA, NeuroSense received positive feedback on the Phase 3 study design, now slated to begin in 2025. The company is in ongoing partnership discussions to advance PrimeC towards regulatory approval and eventual commercialization, including plans to file for early commercialization in Canada.Read Announcement
Data Presentation - April 4,2025Data Presentation Phase 2bDrug: PrimeCAnnounced Date: April 4, 2025Indication: Amyotrophic lateral sclerosisAnnouncementNeuroSense Therapeutics, Ltd. announced that two members of its Scientific Advisory Board will present new data from the Company's Phase 2b trial during the General Neurology and Late Breaker sessions at the 77th Annual American Academy of Neurology (AAN) Meeting.AI SummaryNeuroSense Therapeutics, Ltd. announced that two members of its Scientific Advisory Board will present new data from the company’s Phase 2b trial at the 77th Annual American Academy of Neurology (AAN) Meeting. The presentations will take place during the General Neurology and Late Breaker sessions in San Diego, CA, on April 8, 2025. Dr. Jeremy Shefner will share clinical data demonstrating PrimeC’s safety, tolerability, and efficacy as an oral candidate for ALS, highlighting its potential to reduce ALS progression while engaging multiple biomarker endpoints. Meanwhile, Dr. Jeffrey Rosenfeld will present insights on microRNA modulation and iron-related markers in ALS treatment, shedding light on the mechanism behind PrimeC’s effects. These presentations underscore the company’s focus on advancing a disease-modifying therapy for ALS.Read Announcement
Provided Update - March 20,2025Provided Update Drug: PrimeCAnnounced Date: March 20, 2025Indication: Amyotrophic lateral sclerosisAnnouncementNeuroSense Therapeutics Ltd. announced significant progress toward the early commercialization of PrimeC in Canada.AI SummaryNeuroSense Therapeutics Ltd. announced significant progress toward the early commercialization of its lead ALS therapy, PrimeC, in Canada. Health Canada has invited the company to a pre-New Drug Submission meeting to discuss a potential regulatory pathway for PrimeC. The company is targeting approval by the first half of 2026, which could pave the way for earlier market entry. PrimeC is an innovative, extended-release oral formulation that combines ciprofloxacin and celecoxib. It has shown strong clinical efficacy in trials, including reductions in disease progression and improvements in survival rates. NeuroSense estimates that PrimeC could generate peak annual revenues of $100 to $150 million in the Canadian market alone. This Canadian regulatory development is a critical step in the company’s overall strategy to bring a breakthrough treatment for Amyotrophic Lateral Sclerosis to patients in need.Read Announcement
Positive Results - December 4,2024Positive Results Drug: PrimeCAnnounced Date: December 4, 2024Indication: Amyotrophic lateral sclerosisAnnouncementNeuroSense Therapeutics announce today statistically significant positive results from the 18-month data analysis of the PARADIGM study, evaluating the efficacy of PrimeC in the treatment of Amyotrophic Lateral Sclerosis (ALS).AI Summary NeuroSense Therapeutics announced statistically significant positive results from the 18‐month analysis of its PARADIGM study evaluating PrimeC in ALS treatment. Patients who received PrimeC from the beginning experienced a 33% slower progression of the disease, as shown by nearly an 8-point improvement on the ALS Functional Rating Scale-Revised compared to those who started on placebo before switching to PrimeC. Additionally, continuous treatment with PrimeC led to a striking 58% improvement in survival rates. These results, with a p-value of 0.007, underscore the potential of PrimeC to redefine the standard of care for ALS by offering a more effective approach to slowing disease progression and extending patient survival. Read Announcement